(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Island Travel Guide: Must-Visit Objections for 2024 - 2Christopher Nolan's 'The Odyssey' trailer: See Anne Hathaway, Matt Damon and Tom Holland in 1st look at movie
- 3Freed whale gets stranded again off German coast
- 4SF Chinatown's historic Empress of China building being revived into cultural campus
- 5NASA, in a rare move, cuts space station mission short after an astronaut's medical issue
- Top 20 Wellbeing and Wellness Applications for a Sound Way of life
- German Easter peace marches draw tens of thousands
- This Is Canada's Only Province Without Any Bears
- There was a bit of toilet trouble on NASA's Artemis 2 mission to the moon
- Russia confirms 16 Cameroonian soldiers killed in Ukraine war
- ‘I love this work, but it’s killing me’: The unique toll of being a spiritual leader today
- Iranian president warns of retaliation against Gulf states
- Blue Origin launches New Glenn rocket on company's first NASA-scale science mission
- ISS astronaut evacuation shouldn't interfere with upcoming Artemis 2 moon mission, NASA chief says
